Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

435 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Trivalent adenovirus type 5 HIV recombinant vaccine primes for modest cytotoxic capacity that is greatest in humans with protective HLA class I alleles.
Migueles SA, Rood JE, Berkley AM, Guo T, Mendoza D, Patamawenu A, Hallahan CW, Cogliano NA, Frahm N, Duerr A, McElrath MJ, Connors M. Migueles SA, et al. Among authors: mcelrath mj. PLoS Pathog. 2011 Feb;7(2):e1002002. doi: 10.1371/journal.ppat.1002002. Epub 2011 Feb 24. PLoS Pathog. 2011. PMID: 21383976 Free PMC article.
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.
Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, McElrath MJ, Casimiro DR, Gottesdiener KM, Chodakewitz JA, Corey L, Robertson MN; Step Study Protocol Team. Buchbinder SP, et al. Among authors: mcelrath mj. Lancet. 2008 Nov 29;372(9653):1881-1893. doi: 10.1016/S0140-6736(08)61591-3. Epub 2008 Nov 13. Lancet. 2008. PMID: 19012954 Free PMC article. Clinical Trial.
Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response.
Troyer RM, McNevin J, Liu Y, Zhang SC, Krizan RW, Abraha A, Tebit DM, Zhao H, Avila S, Lobritz MA, McElrath MJ, Le Gall S, Mullins JI, Arts EJ. Troyer RM, et al. Among authors: mcelrath mj. PLoS Pathog. 2009 Apr;5(4):e1000365. doi: 10.1371/journal.ppat.1000365. Epub 2009 Apr 3. PLoS Pathog. 2009. PMID: 19343217 Free PMC article.
Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity.
Graham BS, McElrath MJ, Keefer MC, Rybczyk K, Berger D, Weinhold KJ, Ottinger J, Ferarri G, Montefiori DC, Stablein D, Smith C, Ginsberg R, Eldridge J, Duerr A, Fast P, Haynes BF; AIDS Vaccine Evaluation Group. Graham BS, et al. Among authors: mcelrath mj. PLoS One. 2010 Aug 10;5(8):e11995. doi: 10.1371/journal.pone.0011995. PLoS One. 2010. PMID: 20706632 Free PMC article. Clinical Trial.
Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054).
Peiperl L, Morgan C, Moodie Z, Li H, Russell N, Graham BS, Tomaras GD, De Rosa SC, McElrath MJ; NIAID HIV Vaccine Trials Network. Peiperl L, et al. Among authors: mcelrath mj. PLoS One. 2010 Oct 27;5(10):e13579. doi: 10.1371/journal.pone.0013579. PLoS One. 2010. PMID: 21048953 Free PMC article. Clinical Trial.
Host genetic determinants of T cell responses to the MRKAd5 HIV-1 gag/pol/nef vaccine in the step trial.
Fellay J, Frahm N, Shianna KV, Cirulli ET, Casimiro DR, Robertson MN, Haynes BF, Geraghty DE, McElrath MJ, Goldstein DB; National Institute of Allergy and Infectious Diseases Center for HIV/AIDS Vaccine Immunology; NIAID HIV Vaccine Trials Network. Fellay J, et al. Among authors: mcelrath mj. J Infect Dis. 2011 Mar 15;203(6):773-9. doi: 10.1093/infdis/jiq125. Epub 2011 Jan 28. J Infect Dis. 2011. PMID: 21278214 Free PMC article. Clinical Trial.
435 results